Kallianos Anastasios, Panoutsopoulos Athanasios, Mermigkis Christoforos, Kostopoulos Konstantinos, Papamichail Chrysanthi, Kokkonouzis Ioannis, Kostopoulos Christoforos, Nikolopoulos Ioannis, Papaiwannou Antonis, Lampaki Sofia, Organtzis John, Pitsiou Georgia, Zarogoulidis Paul, Trakada Georgia
Sleep Disorders Unit, Department of Clinical Therapeutics, "Alexandra" General Hospital, Athens School of Medicine, Athens, Greece.
Sleep Disorders Unit, Pulmonary Department, 401 General Army Hospital, Athens, Greece.
Clin Interv Aging. 2015 Aug 19;10:1361-6. doi: 10.2147/CIA.S84199. eCollection 2015.
There is growing research evidence suggesting the presence of endothelial dysfunction and systemic inflammation in patients with obstructive sleep apnea syndrome (OSAS). Continuous positive airway pressure (CPAP) is the most effective method for treating OSAS; nonetheless, the effects of CPAP on the aforementioned pathophysiologic pathways as well as on the systemic disease that result or coexist with the OSAS remain elusive.
To assess the effect of 3-month CPAP therapy on endothelial-dependent dilation, plasma levels of inflammatory markers, blood pressure (BP), and glucose control on male and female patients with OSAS.
Our study group consisted of 40 (24 males and 16 females) patients with no prior history of cardiovascular disease, with an apnea-hypopnea index ≥15, who were assigned to receive CPAP treatment. Measurements of flow-mediated dilation (FMD), 24-hour ambulatory BP, and blood analysis were performed at baseline and 3 months after CPAP therapy.
Baseline FMD values were negatively correlated with the apnea-hypopnea index (r=-0.55, P=0.001). After 3 months of CPAP, there was an increase in the FMD values (5.40%±2.91% vs 3.13%±3.15%, P<0.05) and a significant reduction in the patients' 24-hour systolic BP (122.82±11.88 mmHg vs 130.24±16.75 mmHg, P<0.05), diastolic BP (75.44±9.14 mmHg vs 79.68±11.09 mmHg, P<0.05), and pulse pressure (47.38±9.77 mmHg vs 52.72±11.38 mmHg, P<0.05); daytime systolic BP (125.76±12.69 mmHg vs 132.55±17.00 mmHg, P<0.05) and diastolic BP (77.88±10.39 mmHg vs 82.25±11.01 mmHg, P<0.05); nighttime systolic BP (118.17±13.16 mmHg vs 126.22±17.42 mmHg, P<0.05) and pulse pressure (46.61±10.76 mmHg vs 52.66±11.86 mmHg, P<0.05); and C-reactive protein and HbA1c levels (0.40 [0.40-0.70] mg/L vs 0.60 [0.40-0.84] mg/L and 5.45%±0.70% vs 5.95%±1.08%, respectively; P<0.05). When divided by sex, only male patients produced similar statistically significant results, while female patients failed to show such associations.
Our results suggest that CPAP therapy improves the endothelial function, the BP, and the glucose control in male patients with OSAS. Further research is warranted in order to verify these results and to further elucidate the impact of CPAP on the cardiovascular risk of male and female patients with OSAS.
越来越多的研究证据表明,阻塞性睡眠呼吸暂停综合征(OSAS)患者存在内皮功能障碍和全身炎症。持续气道正压通气(CPAP)是治疗OSAS最有效的方法;然而,CPAP对上述病理生理途径以及对由OSAS导致或与之共存的全身性疾病的影响仍不明确。
评估3个月的CPAP治疗对OSAS男性和女性患者内皮依赖性舒张、炎症标志物血浆水平、血压(BP)和血糖控制的影响。
我们的研究组由40名(24名男性和16名女性)无心血管疾病史、呼吸暂停低通气指数≥15的患者组成,他们被分配接受CPAP治疗。在基线和CPAP治疗3个月后进行血流介导的舒张功能(FMD)、24小时动态血压测量和血液分析。
基线FMD值与呼吸暂停低通气指数呈负相关(r=-0.55,P=0.001)。CPAP治疗3个月后,FMD值增加(5.40%±2.91%对3.13%±3.15%,P<0.05),患者24小时收缩压(122.82±11.88 mmHg对130.24±16.75 mmHg,P<0.05)、舒张压(75.44±9.14 mmHg对79.68±11.09 mmHg,P<0.05)和脉压(47.38±9.77 mmHg对52.72±11.38 mmHg,P<0.05)显著降低;白天收缩压(125.76±12.69 mmHg对132.55±17.00 mmHg,P<0.05)和舒张压(77.88±10.39 mmHg对82.25±11.01 mmHg,P<0.05);夜间收缩压(118.17±13.16 mmHg对126.22±17.42 mmHg,P<0.05)和脉压(46.61±10.76 mmHg对52.66±11.86 mmHg,P<0.05);以及C反应蛋白和糖化血红蛋白水平(分别为0.40[0.40 - 0.70]mg/L对0.60[0.40 - 0.84]mg/L和5.45%±0.70%对5.95%±1.08%;P<0.05)。按性别划分时,只有男性患者产生了类似的统计学显著结果,而女性患者未显示出此类关联。
我们的结果表明,CPAP治疗可改善OSAS男性患者的内皮功能、血压和血糖控制。有必要进行进一步研究以验证这些结果,并进一步阐明CPAP对OSAS男性和女性患者心血管风险的影响。